|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Collectively, our findings demonstrate that FN exerts the anticarcinogenic effect on prostate cancer in vitro, in which the underlying mechanisms are associated with enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway, thus triggering apoptosis in tumor cells.
|
24666255 |
2014 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The expressions of multiple prognostic molecular markers for PC (Ki-67, p53 and bcl-2) were immunohistochemically measured using the SA.
|
24220327 |
2014 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We found a significant increase in both mRNA expression of the anti-apoptotic Bcl-2 gene and VDAC1 gene in prostate cancer tissue in comparison with their normal counterparts.
|
25177836 |
2014 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may, in part, regulate response to docetaxel.
|
25053345 |
2014 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This synergistic therapy was associated with the induction of apoptotic cell death with a decreased Bcl2 to Bax expression ratio and increased expression of cleaved caspase 3 and caspase 9 in the prostate cancer xenograft.
|
23726840 |
2013 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BCL2 mRNA expression in the same collective of prostate cancer tissue samples was associated with higher Gleason score and extracapsular extension of the tumour (pT3).
|
23612742 |
2013 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The prostate cancer antigen gene 3 (PCA3) is embedded in an intron of a second gene BMCC1 (Bcl2-/adenovirus E1B nineteen kDa-interacting protein 2 (BNIP-2) and Cdc42GAP homology BCH motif-containing molecule at the carboxyl terminal region 1) which is also upregulated in prostate cancer.
|
24040105 |
2013 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Antisense oligonucleotides (oligos) have been employed against prostate cancer models targeting growth-regulatory proteins, and at least one oligo (against bcl-2) has reached clinical trial.
|
23160675 |
2013 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The combination of sorafenib with Bcl-2 antagonists, such as ABT737, may constitute a promising therapeutic strategy against prostate cancer.
|
22278289 |
2012 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The relation of Bcl-2 overexpression and copy number gains or translocation of the BCL-2 gene in prostate cancer under hormone-naïve conditions is unknown.
|
22024950 |
2012 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In this study, we aimed our attention on determining the expression of Bcl-2, c-Fos, c-Jun, Ki-67, NF-κB and p53 genes in two prostate cell lines, as the 22Rv1 cell line, a model of aggressive partially androgen-sensitive prostate cancer and the PNT1A cell line, a normal prostate cell line model.
|
22766626 |
2012 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We examined the effect of hypoxia on RUNX2 expression and the role of RUNX2 in the regulation of Bcl-2 and apoptosis resistance in prostate cancer.
|
23073173 |
2012 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
NEU3 silencing with siRNA in prostate cancer PC-3 and LNCaP cells resulted in increased expression of differentiation markers and in cell apoptosis, but decrease in Bcl-2 as well as a progression-related transcription factor, early growth response gene (EGR-1).
|
21681193 |
2012 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that sHA is a potent inhibitor of prostate cancer. sHA blocked the proliferation, motility, and invasion of LNCaP, LNCaP-AI, DU145, and LAPC-4 prostate cancer cells, and induced caspase-8-dependent apoptosis associated with downregulation of Bcl-2 and phospho-Bad. sHA inhibited Akt signaling including androgen receptor (AR) phosphorylation, AR activity, nuclear factor κB (NFκB) activation, and VEGF expression.
|
21555367 |
2011 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A natural BH3-mimetic, small-molecule inhibitor of Bcl-2, (-)-gossypol, shows promise in ongoing phase II and III clinical trials for human prostate cancer.
|
20577262 |
2011 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
|
19576799 |
2011 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the BCL2 -938C>A polymorphism is an independent predictor of relapse-free and overall survival in patients with prostate cancer.
|
21207420 |
2011 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We investigated the effect of androgen deprivation therapy (ADT) on BCL-2 expression in prostate cancer tissues.
|
21785821 |
2011 |
|
Prostate carcinoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, BCL2 was also found to be frequently silenced in PCa due to aberrant promoter methylation, thus supporting a future role for apoptosis-targeted therapy in prostate cancer.
|
20464497 |
2010 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
p53, Bcl-2 and AgNOR tissue markers: model approach in predicting prostate cancer characteristics.
|
20146885 |
2010 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
|
20519142 |
2010 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
BCl2 antagonists, such as HA-14-1, enhanced the effects of azacitidine in these two prostate cancer models.
|
19153211 |
2009 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BCL-xL, a hypoxia-responsive, anti-apoptotic protein of the Bcl-2 family, is also overexpressed in prostate carcinoma and many other cancers.
|
19211554 |
2009 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.
|
19117992 |
2009 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.
|
18475287 |
2009 |